Please assess the completion status of the following clinical trial:

Trial Title: A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documentation of nirmatrelvir/ritonavir treatment with patient-reported 100% compliance. Symptom alleviation or resolution in COVID-19 signs/symptoms followed by a worsening (rebound) of signs/symptoms after completing an initial 5-day course of nirmatrelvir/ritonavir~* Onset of rebound in COVID-19 symptoms within 2 weeks (14 days) after the completion of the initial 5-day course of nirmatrelvir/ritonavir.~* Onset of rebound in signs/symptoms attributable to COVID-19 within 48 hours prior to randomization and ≥1 sign/symptom attributable to COVID-19 present on the day of randomization.~* SARS-CoV-2 infection as determined by rapid antigen testing within 24 hours prior to randomization~* At least 1 characteristic or underlying medical condition associated with an increased risk of developing severe illness from COVID-19.~Exclusion Criteria:~* Current need for hospitalization, hospitalized for the COVID-19 infection or anticipated need for hospitalization within 24 hours after randomization~* History of severe chronic liver disease~* Receiving dialysis or have known age-specific estimated glomerular filtration rate (eGFR) or estimated creatinine clearance (eCrCl) \<30 mL/min/1.73 m2 at screening as measured by a serum creatinine point of care device~* Oxygen saturation of \<92% on room air obtained at rest within 24 hours prior to randomization~* Immunocompromised.~* Current use of any prohibited concomitant medication(s)~* Females who are pregnant and \<14 weeks gestation

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nirmatrelvir plus ritonavir for 5 days (Type: EXPERIMENTAL): Nirmatrelvir (2 tablets) plus ritonavir (1 capsule) will be given by mouth every 12 hours for 5 days
- placebo plus ritonavir for 5 days (Type: OTHER): placebo (2 tablets) plus ritonavir (1 capsule) will be given by mouth every 12 hours for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).